Trials / Completed
CompletedNCT02886468
DEpth of EPinephrine Delivery With Auto-injectors Devices
Determinants of Muscle - Skin Distance at the Injection Site in Patients With an Indication for the Use of Epinephrine Auto- Injector Pens
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Centre Hospitalier Régional Metz-Thionville · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. Although there are several causes of fatal anaphylaxis, food allergy is one of the most common. Epinephrine is recommended as the initial treatment of choice for anaphylaxis. A delay in epinephrine administration may contribute to an increased risk of death. Therefore, the World Allergy Organization recommends that, for the treatment of anaphylaxis, epinephrine solution be administered intramuscularly in the mid-anterolateral thigh. In France 3 auto-injector pens are available: Anapen®, Epipen® and Jext®. For weight\> 30 kg, the devices have a needle size respectively of 7.49 mm, 15.02 mm and 15.36 mm. For the weights between 15 and 30 kg needle size is 7.49 mm to 12.7 mm and Anapen® for Epipen® and Jext®. Several studies suggest that the needle length needle is sometim
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | skin ultrasound |
Timeline
- Start date
- 2016-08-26
- Primary completion
- 2021-05-04
- Completion
- 2021-08-16
- First posted
- 2016-09-01
- Last updated
- 2021-08-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02886468. Inclusion in this directory is not an endorsement.